Articles Vol. 67 No. 8 25/08/2026

COST-EFFECTIVENESS EVALUATION OF VANCOMYCIN THERAPEUTIC DRUG MONITORING WITH TARGET AUC/MIC AT CU CHI REGIONAL GENERAL HOSPITAL DURING 2024-2025

Hoang Thy Nhac Vu1,2, Vo Thi Thanh Van3,4, Phan Ngo Diem Trang3,4, Nguyen Thi Hoang Tho3,4, Pham Ngoc Thuy Tien1,2, Phan Kim Ngoc3,4
1 University of Medicine and Pharmacy at Ho Chi Minh City
2 Đại học Y Dược Thành phố Hồ Chí Minh
3 Cu Chi Regional General Hospital
4 Bệnh viện đa khoa khu vực Củ Chi
DOI: 10.52163/yhc.v67i8.6356
28 Views
0 Downloads
Keywords
Cost-effectiveness, Vancomycin TDM, Cu Chi Regional General Hospital
Abstract

Objective: This study aimed to evaluate the cost-effectiveness of vancomycin therapeutic drug monitoring based on the area under the concentration–time curve to minimum inhibitory concentration ratio - AUC/MIC (TDM AUC).

Subjects and Methods: The study was conducted based on data from insured patients receiving vancomycin at Cu Chi Regional General Hospital during two periods: before TDM implementation (01-06/2024) and after TDM application (01-06/2025). The analysis was performed from the healthcare system perspective and focused on direct medical costs and clinical outcomes.

Results: The implementation of TDM AUC was identified as a dominant strategy, simultaneously improving clinical outcomes and reducing costs, saving 9.4 million VND per additional clinical response achieved. Furthermore, TDM AUC significantly reduced the risk of acute kidney injury (AKI), corresponding to savings of approximately 8.7 million VND per AKI case prevented. One-way sensitivity and probabilistic analyses demonstrated consistent results, maintaining cost-effectiveness advantages across most iterations.

Conclusion: This study provided additional economic evidence for TDM AUC implementation. These results provide a foundation for treatment decision-making and broader application in healthcare facilities with similar conditions.

References
[1]
Rybak M. J., Le J., Lodise T. P., et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2020;77(11):835-64, DOI: 10.1093/ajhp/zxaa036. Google Scholar
[2]
Claus B. O. M., De Smedt D., De Cock P. A. Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost-benefit analysis. The Journal of antimicrobial chemotherapy. 2025;80(3):857-67, DOI: 10.1093/jac/dkaf011. Google Scholar
[3]
Kim Y., Kim S., Park J., Lee H. Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients. Journal of personalized medicine. 2022;12(2), DOI: 10.3390/jpm12020163. Google Scholar
[4]
Trương Thúy Quỳnh, Huỳnh Phương Thảo, Hà Mai Phương, et al. Đánh giá chi phí – hiệu quả của vancomycin trước và sau khi áp dụng kỹ thuật theo dõi nồng độ thuốc trong máu bằng thông số AUC mục tiêu tại Bệnh viện bệnh Nhiệt Đới Thành phố Hồ Chí Minh giai đoạn 2020-2021. Tạp chí Y học Việt Nam. 2024;534(1B), DOI: 10.51298/vmj.v534i1B.8273. Google Scholar
[5]
Office National Statistics. Consumer price index, gold price index and US dollar price index in June, second quarter and first 6 months of 2025 [Available from: https://www.nso.gov.vn/en/data-and-statistics/2025/07/consumer-price-index-gold-price-index-and-us-dollar-price-index-in-june-second-quarter-and-first-6-months-of-2025/. Google Scholar
[6]
Bộ Y tế (2024). Hướng dẫn chẩn đoán và điều trị bệnh thận mạn và một số bệnh lý thận.Quyết định 2388/QĐ-BYT ban hành ngày 12/08/2024. Google Scholar
[7]
Lee B. V., Fong G., Bolaris M., et al. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(9):1346.e1-.e7, DOI: 10.1016/j.cmi.2020.11.008. Google Scholar
[8]
Neely M. N., Kato L., Youn G., et al. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. Antimicrobial agents and chemotherapy. 2018;62(2), DOI: 10.1128/aac.02042-17. Google Scholar